Unknown PHASE4 INTERVENTIONAL NCT00277693

Cardiovascular Protective Effect of Spironolactone in Hemodialysis

Protective Mechanisms of Aldosterone Antagonists and Their Effects on Cardiovascular Damage in Chronic Renal Failure: Clinical and Experimental Studies

Sponsor: Universidad de los Andes, Chile

Conditions Hemodialysis

Interventions Spironolactone (drug)

Updated 6 times since 2017 Last updated: Jan 12, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Hemodialysis, this trial is ongoing. The trial is conducted by Universidad de los Andes, Chile and has accumulated 6 data snapshots since 2026. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Oct 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Jan 2021 — Oct 2021 [monthly]

Unknown Status PHASE4
Jan 2019 — Jan 2021 [monthly]

Unknown Status PHASE4

▶ Show 1 earlier version

Jan 2017 — Jan 2019 [monthly]

Unknown Status PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Universidad de los Andes, Chile

Data source: Universidad de los Andes, Chile

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Santiago, Chile